To describe patient characteristics of women diagnosed with generalized unprovoked vulvodynia (GUV) and to estimate efficacy and tolerability of treatment.
Material and methods
Retrospective observational study in 241 women who presented with GUV at three vulvar disease clinics in Rotterdam, The Netherlands during 1996–2013. Main outcome was efficacy of amitriptyline, gabapentin or pregabalin treatment.
The median duration of symptoms was 24 months and median age 62 years (range 36–89). Most of the patients reported a burning sensation, often worsened by sitting, urinating or having intercourse. Treatment with either amitriptyline, gabapentin or pregabalin produced long lasting pain relief in 60% and temporary pain relief in 10%, while treatment was not successful in 30% of the patients. Around 30% of the patients had to stop their medication due to side effects.
In 44 of the 241 (18%) women signs of vulvar dermatoses were present that could not explain the symptoms. These women experienced the same therapeutic efficacy as those without any visible abnormalities (chi-square goodness of fit p = 0.49).
Amitriptyline, gabapentin and pregabalin produced long lasting pain relief in most of the women with GUV. The 2015 International Society for the Study of Vulvovaginal Disease nomenclature acknowledges the concomitant presence of vulvar dermatoses and vulvodynia. This enables treatment of both conditions simultaneously, a situation that occurs regularly according to our study. We advocate that women with symptoms of GUV, with or without the presence of vulvar dermatoses, receive a therapeutic trial with drugs such as amitriptyline.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
J. Bornstein, A. Goldstein, D. Coady, Consensus terminology and classification of persistent vulvar pain 2015 [02-09-2016], Available from: http://issvd.org/wp-content/uploads/2015/09/consensus-terminology-of-Vulvar-Pain-V5.pdf.
- Effects of vulvodynia on quality of life.J Am Acad Dermatol. 2009; 60: 70-76
- Economic burden and quality of life of vulvodynia in the United States.Curr Med Res Opin. 2012; 28: 601-608
- 2003 ISSVD terminology and classification of vulvodynia: a historical perspective.J Reprod Med. 2004; 49: 772-777
- Approach to the diagnosis and treatment of vulvar pain.Dermatol Ther. 2010; 23: 485-504
- New concepts in vulvodynia.Am J Obstet Gynecol. 2003; 189: S24-S30
- Chronic vulvar pain in a cohort of post-menopausal women: atrophy or vulvodynia?.Womens Midlife Health. 2016; : 2
- Vulvodynia: characteristics and associations with comorbidities and quality of life.Obstet Gynecol. 2006; 107: 617-624
- A systematic review of the utility of antidepressant pharmacotherapy in the treatment of vulvodynia pain.J Sex Med. 2013; 10: 2497-2505
- Treatment of vulvodynia with tricyclic antidepressants: efficacy and associated factors.J Low Genit Tract Dis. 2006; 10: 245-251
- 2013 vulvodynia guideline update.J Low Genit Tract Dis. 2014; 18: 93-100
- A systematic review of the utility of anticonvulsant pharmacotherapy in the treatment of vulvodynia pain.J Sex Med. 2013; 10: 2000-2008
- Anticonvulsant pharmacotherapy for generalized and localized vulvodynia: a critical review of the literature.J Psychosom Obstet Gynaecol. 2013; 34: 133-138
- Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial.Obstet Gynecol. 2010 Sep; 116: 583-593
Published online: October 31, 2017
Accepted: October 30, 2017
Received in revised form: September 28, 2017
Received: July 6, 2017
© 2017 Published by Elsevier Ireland Ltd.